Inclusion Criteria:

- Meets one of the following sets of criteria:

- Dose-escalation group:

- Histologically and/or cytologically confirmed solid malignancy

- Metastatic or unresectable disease

- Disease for which standard curative or palliative measures do not exist or
are no longer effective

- Expansion group:

- Histologically and/or cytologically confirmed endometrial (endometrioid,
uterine papillary serious carcinoma, or carcinosarcoma) or renal cell
cancer

- Metastatic or unresectable disease

- Disease for which standard curative or palliative measures do not exist or
are no longer effective

- Measurable or non-measurable disease

- Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥
1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional
techniques or as ≥ 10 mm with spiral CT scan

- No known brain metastases

- ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)

- Life expectancy > 12 weeks

- Leukocytes ≥ 3,000/mm^3

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)

- Total bilirubin normal

- AST/ALT ≤ 2.5 times upper limit of normal

- Serum creatinine normal OR creatine clearance ≥ 60 mL/min

- Fasting cholesterol ≤ 350 mg/dL (9.0 mmol/L)

- Fasting triglycerides ≤ 400 mg/dL (4.56 mmol/L)

- No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or
hypokalemia defined as less than the lower limit of normal for the institution,
despite adequate electrolyte supplementation

- Note: it is acceptable to use corrected calcium when interpreting calcium levels

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use two effective forms of contraception (i.e., barrier
contraception and one other method of contraception) for ≥ 4 weeks before, during,
and for ≥ 12 months after completion of study therapy

- Able to swallow medication

- No malabsorption syndrome or other condition that would interfere with intestinal
absorption

- No diarrhea ≥ grade 2 that is not under control with standard anti-diarrhea
medications

- No uncontrolled concurrent illness including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable anginal pectoris

- Cardiac arrhythmia other than chronic, stable atrial fibrillation

- Psychiatric illness or social situations that would limit compliance with study
medications

- QTc ≤ 450 msec in males and a QTc ≤ 470 msec in females, as measured by ECG using
Bazett formula

- No history of risk factors for QT interval prolongation including, but not limited
to, a family or personal history of any of the following:

- Long QT syndrome

- Torsades de pointes

- Recurrent syncope without known etiology

- Sudden unexpected death

- No pre-existing significant pulmonary infiltrates of unknown origin

- No serologic positivity for hepatitis A, B, or C or history of liver disease or other
forms of hepatitis or cirrhosis

- No HIV-positive patients on combination antiretroviral therapy

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to gamma-secretase inhibitor RO4929097 or temsirolimus

- Female patients may not donate ova during or after study treatment

- Male patients may not donate sperm during and for ≥ 12 months after completion of
study treatment

- Patients may not donate blood during and for ≥ 12 months after completion of study
treatment

- Any number of prior therapies allowed

- Recovered from side effects of previous systemic anticancer therapy to < CTCAE grade
2 toxicity (except alopecia)

- Concurrent leuteinizing hormone-releasing hormone agonist allowed in patients with
castration-resistant prostate cancer

- No prior gamma-secretase inhibitor or any inhibitor of the PI3K/Akt/mTOR pathway

- At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for
carmustine, nitrosoureas, or mitomycin C)

- Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for
symptomatic palliation

- No other concurrent investigational agents

- No concurrent medications with narrow therapeutic indices that are metabolized by
cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)

- No concurrent medications that are strong inducers, inhibitors, or substrates of
CYP3A4

- No antiarrhythmics or other concurrent medications with known potential to prolong QT
interval

- No concurrent food that may interfere with the metabolism of gamma-secretase
inhibitor RO4929097, including grapefruit or grapefruit juice

- No other concurrent anticancer agents or therapies